40.22 +0.10 (0.25%)
After hours: 7:39PM EST
|Bid||40.11 x 3200|
|Ask||40.22 x 1300|
|Day's Range||39.83 - 40.22|
|52 Week Range||26.27 - 40.33|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||33.71|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.80|
MARLBOROUGH, Mass. , Feb. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under ...
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured notes offering of Boston Scientific Corporation ("Boston Scientific"). There are no changes to Moody's existing ratings of Boston Scientific including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. Boston Scientific's Baa2 senior unsecured ratings reflects its meaningful scale in the medical device industry with revenues of approximately $10 billion.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue and EPS growth trajectoryIn its fourth-quarter earnings press release, Boston Scientific (BSX) reported revenues of $9.82 billion for fiscal 2018, a YoY rise of
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidanceIn the company’s fourth-quarter earnings conference call, Boston Scientific (BSX) has guided for an adjusted gross margin of 72%–73% for fiscal 2018,
Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality. BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Expense projections for fiscal 2019 In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted SG&A (selling, general, and
Marlborough medical device giant Boston Scientific is close to settling nearly 50,000 lawsuits related to a controversial mesh implant product that thousands of women allege led to infections, urinary problems, pain and other problems.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings projections for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted EPS of $1.53–$1.58 for
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%, YoY organic
How Boston Scientific and Abbott Laboratories Stack UpStock price movementsOn February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its
Boston Scientific Corp is a developer, manufacturer, and marketer of medical devices. Warning! GuruFocus has detected 6 Warning Signs with MRK. For the last quarter Boston Scientific Corp reported a revenue of $2.6 billion, compared with the revenue of $2.4 billion during the same period a year ago.
MARLBOROUGH, Mass. , Feb. 14, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 ...
To receive further updates on this Boston Scientific (NYSE:BSX) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of Strategic Trader today.We are opening a new bullish trade on Boston Scientific (NYSE:BSX). BSX is a medical device company that manufactures coronary stent systems, cancer treatment catheter systems, Parkinson's deep brain stimulation systems and more.Medical device companies, like BSX, have been steady performers on Wall Street since 2013 as an increasing number of Americans have gained insurance coverage and are now able to receive treatment for their health conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Strong Earnings and New AcquisitionsBSX released its quarterly earnings numbers last week on Feb. 6, before market open, and thrilled investors by announcing revenue numbers that were in-line with expectations and by beating earnings expectations by $0.07 per share -- coming in at $2.56 billion and $0.27 per share, respectively.Medical device companies have been able to maintain their pricing power in negotiations with insurance companies. This is a trend that is likely to continue well into the future, so BSX could see strong revenue and earnings for years to come.BSX is also expanding the medical devices it manufactures, which could result in more sales. In November 2018, it announced it would acquire BTG plc., the surgical device manufacturer. BSX also just acquired Millipede, Inc., a company that developed technology for dealing with mitral regurgitation. Breaking Above $38The company's positive earnings announcement seems to have been the catalyst investors had been waiting for to break the stock out of the consolidation range it had been in since September 2018. The post-earnings breakout at $38 completed and confirmed a "broadening-wedge" bullish continuation pattern for the stock.Daily Chart of Boston Scientific (BSX) -- Chart Source: TradingViewWhereas it had served as resistance before earnings, we anticipate $38 is now going to serve as a strong support level moving forward. If it does, we can sell slightly out-of-the-money puts on the stock and keep our entire premium when they expire. That would give us the chance to roll out our puts and collect even more income.To find out which BSX puts we're selling -- and to get access to our full portfolio of income-generating trades -- consider signing up for risk-free trial subscription to Strategic Trader today. InvestorPlace advisers John Jagerson and S. Wade Hansen, both Chartered Market Technician (CMT) designees, are co-founders of LearningMarkets.com, as well as the co-editors of Strategic Trader.Follow our Facebook page to receive each Trade of the Day direct to your News Feed -- and join the conversation.Compare Brokers The post BSX is Breaking Out for the First Time Since September 2018 appeared first on InvestorPlace.
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll evaluate Boston Scientific Corporation (NYSE:BSX)Read More...
Boston Scientific Corp NYSE:BSXView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $15.35 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. BSX credit default swap spreads are decreasing, indicating some improvement in the market's perception of the company's credit worthiness. Additionally, they are within the middle of the range set over the last three years.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Stocks finally found their ceiling, right where it would have been expected. The S&P 500's close of 2731.61 was down 0.22% from Tuesday's last trade, with the 200-day moving average line confirming its role as a technical problem.Video game companies led the drop. Electronic Arts (NASDAQ:EA) kicked off the meltdown, falling 13% in response to disappointing guidance. Shareholders applied the same doubt to rivals Activision Blizzard (NASDAQ:ATVI) and Take-Two Interactive Software (NASDAQ:TTWO), however, sending them 10% and 14% lower on Wednesday.Not every name ended yesterday in the red though. Snapchat parent Snap (NYSE:SNAP) jumped 22% on Wednesday after posting encouraging Q4 results and then being upgraded by a handful of analysts.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAll of those moves are far too volatile to chase, however. Instead, tamer stocks charts like those of FirstEnergy (NYSE:FE), Boston Scientific (NYSE:BSX) and Mondelez International (NASDAQ:MDLZ) are shaping up as better, more reliable prospects. Boston Scientific (BSX)During the latter third of last year, Boston Scientific shares broke above a long-standing trading range. Though impressive, it also appeared to be a setup for a major pullback. * The 9 Best Stocks to Invest In During a Manic Market We got that pullback, though not fully. Since the end of December, MDLZ has pushed its way back above that resistance line. With a tankful of momentum at its disposal, Boston Scientific could forge ahead to higher highs again. There's one ceiling that needs to be broken first, though it was cracked yesterday. Click to Enlarge • The long-standing trading range is plotted with white dashed lines on the weekly chart. The renewed break out of that range validates the first bullish wave.• The more immediate technical resistance lies at $38.60, where shares peaked three times in October and November. BSX closed above that level on Wednesday, but it's far from set in stone.• It's only a fairly recent development, but there's a large amount of volume behind the buying spree that took shape late last year. Mondelez International (MDLZ)Mondelez International shares have been a huge winner since late December, with last week's 6.6% serving as a big exclamation point. It would be easy to be lured into being a buyer. Given the scope of the move in the rearview mirror, it would be easy to excuse this week's breather.There may be more to this week's pause than just a chance for the rest of the market to catch up, however. A closer, bigger-picture look reveals this is where one would expect the gain to run out of gas and then pull back. Click to Enlarge • In a long-term, philosophical sense, MDLZ has been in the habit of back-and-forth action. It doesn't remain overbought or oversold for very long, and the current overbought condition isn't apt to last long either.• Bolstering the likelihood that a ceiling has already been hit is the fact that last week's and this week's highs around $48 are in line with one of the most frequently hit ceilings going all the way back to 2016.• In the near term, Mondelez shares have stalled at a resistance level that has now tagged the past three major peaks going back to September. That line is plotted in yellow on both stock charts. FirstEnergy (FE)Finally, FirstEnergy isn't in trouble yet. And, it may not slip into a downtrend -- the stock's still on the upper side of most of its key moving average lines.When taking a step back and looking at the chart's performance from a distance, however, it's difficult not to notice the current tide has shifted from last year's bullishness to brewing bearishness. Click to Enlarge • The clues are subtle, but they're there. Chief among them is the fact that the divergence of the moving average lines we saw early last year has turned into a convergence. FE has also made its first lower high in months.• In the weekly timeframe, the MACD lines have been bearish since October.• Though the tide may be modestly bearish, until FirstEnergy falls below and stays below the white 200-day moving average line, there's still hope for a rebound move.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post 3 Big Stock Charts for Thursday: FirstEnergy, Boston Scientific and Mondelez appeared first on InvestorPlace.
Stocks that moved substantially or traded heavily on Wednesday: Snap Inc., up $1.55 to $8.59 The social media company beat Wall Street forecasts on a surge in revenue that helped slash its quarterly loss ...
Boston Scientific stock approached a breakout Wednesday after the medical giant topped fourth-quarter earnings expectations, though 2019 and first-quarter earnings guidance lagged.
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.